The role of the intestinal microbiome in cancer immunotherapy

肠道微生物组在癌症免疫治疗中的作用

基本信息

项目摘要

ABSTRACT The gut microbiota consists of a community of diverse microbes and has many effects on human (patho)physiology. Microbiome composition has been associated with many diseases, but causal inference is often lacking. Preclinical and clinical studies have demonstrated that the intestinal microbiota can regulate innate and adaptive immunity, including T cell and antitumor immunity after allogeneic hematopoietic cell transplantation (allo-HCT) and checkpoint blockade. My lab has focused on the role of gut microbiota in outcomes of allo-HCT and immunotherapy. For example, we showed that microbiota composition undergoes significant and frequent changes during allo-HCT and that lower intestinal microbiota diversity is associated with increased mortality. We also found that dominance by certain species, most frequently Enterococcus, is associated with lethal graft-versus-host disease (GVHD); that exposure to certain antibiotics is associated with worse outcomes following allo-HCT and chimeric antigen receptor T cell (CART) therapy; and that hematopoietic reconstitution is associated with the presence of beneficial flora. These studies have been translated into clinical trials using autologous fecal microbiota transplant, administration of defined bacterial consortia, and antibiotic stewardship to spare and/or restore the commensal flora. The overarching hypothesis of this proposal is that the intestinal microbiome is an important modulator of innate and adaptive immunity in the setting of cancer immunotherapy. While immunotherapies are curative in some recipients, improving their efficacy and abating toxicities are unmet needs in oncology. The major goals are to improve cancer immunotherapy by targeting the intestinal microbiome based on preclinical and clinical studies. Examples of our ongoing and planned studies include: a) development of a new pipeline for microbiome analysis, b) preclinical and clinical projects regarding intestinal microbiome and CART, c) new techniques to analyze the effects of diet and drugs on the intestinal microbiome, and d) preclinical and clinical studies regarding immune modulation by bile acids, as an example how we study the mechanisms by which the intestinal microbiome can modulate immunity and cancer immunotherapy. We have organized a multicenter global consortium to collect fecal samples (funded separately from this application) along with a novel multi-omic approach to integrate patient, microbiome, and tumor profiling modalities using a computational platform (MSK-MIND) for data harmonization and machine learning. These investigations will be performed via perpetual dialogue between work with mice and humans: human studies enable us to observe correlations, develop hypotheses, and test therapeutic strategies; animal studies enable us to establish or refute causal relationships between microbiota and host immunology and to obtain mechanistic insights. These data will inform the future development of clinical trials to test therapeutic strategies to enhance efficacy and decrease toxicity in patients receiving cancer immunotherapy, such as CART and allo-HCT.
摘要 肠道菌群由多种微生物组成,对人体有多种影响 (病理)生理学。微生物组组成与许多疾病有关,但因果推断是 往往缺乏。临床前和临床研究表明,肠道微生物群可以调节先天性 获得性免疫,包括异基因造血细胞移植后的T细胞免疫和抗肿瘤免疫 移植(allo-HCT)和检查点阻断。我的实验室专注于肠道微生物群在 allo-HCT和免疫治疗的结果。例如,我们发现微生物群的组成经历了 allo-HCT期间显著和频繁的变化以及较低的肠道微生物群多样性与 增加死亡率。我们还发现,某些物种的优势,最常见的是肠球菌, 与致命的移植物抗宿主病(GVHD)相关;暴露于某些抗生素与 allo-HCT和嵌合抗原受体T细胞(CART)治疗后的结局更差; 重建与有益植物群的存在有关。这些研究已经转化为临床 使用自体粪便微生物群移植、施用确定的细菌聚生体和抗生素的试验 保护和/或恢复植物植物群。这一建议的首要假设是, 肠道微生物组是癌症背景下先天和适应性免疫的重要调节剂 免疫疗法虽然免疫疗法在一些接受者中是治愈性的,但提高其疗效并减轻其不良反应, 毒性是肿瘤学中未满足的需求。主要目标是通过靶向肿瘤细胞来改善癌症免疫治疗。 基于临床前和临床研究的肠道微生物组。我们正在进行和计划进行的研究的例子 包括:a)开发用于微生物组分析新管道,B)临床前和临床项目, 肠道微生物组和CART,c)分析饮食和药物对肠道微生物的影响的新技术, 微生物组,和d)关于胆汁酸的免疫调节的临床前和临床研究,作为实例 我们如何研究肠道微生物组调节免疫和癌症的机制 免疫疗法。我们组织了一个多中心的全球联盟来收集粪便样本(单独资助 沿着一种新的多组学方法来整合患者、微生物组和肿瘤谱 使用计算平台(MSK-MIND)进行数据协调和机器学习。这些 研究将通过小鼠和人类工作之间的永久对话进行:人类研究 使我们能够观察相关性,发展假设,并测试治疗策略;动物研究使 我们建立或反驳微生物与宿主免疫学之间的因果关系,并获得机制 见解.这些数据将为临床试验的未来发展提供信息,以测试治疗策略, 在接受癌症免疫疗法如CART和allo-HCT的患者中,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marcel R M van den Brink其他文献

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation
  • DOI:
    10.1182/blood-2022-162386
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Doris M Ponce;Jonathan U Peled;Bindu Tejura;Christopher Ford;Marcel R M van den Brink;Mary Jane Lombardo;Satyajit Kosuri;Nandita Khera;Zachariah Defilipp;Lisa von Moltke
  • 通讯作者:
    Lisa von Moltke
Microbial Changes in Response to a Plant-Based Diet and/or Supplements in SMM Patients: A National Multi-Arm Randomized Prospective Telehealth Study Via Healthtree: The Nutrition Prevention (NUTRIVENTION-2) Study
针对 SMM 患者基于植物的饮食和/或补充剂的微生物变化:通过 Healthtree 进行的一项全国多臂随机前瞻性远程医疗研究:营养预防(NUTRIVENTION-2)研究
  • DOI:
    10.1182/blood-2022-160241
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
    23.100
  • 作者:
    Francesca Castro;Nathan W. Sweeney;Andriy Derkach;Kadiatou Traore;Aishwarya Anuraj;Laura Guttentag;Jenna Blaslov;Ana Sahagun;Jay Hydren;Cynthia Chmielewski;Terry Golombick;Justin R Cross;Jun J Mao;Marcel R M van den Brink;Saad Usmani;Jennifer M. Ahlstrom;Alexander M Lesokhin;Urvi A Shah
  • 通讯作者:
    Urvi A Shah

Marcel R M van den Brink的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marcel R M van den Brink', 18)}}的其他基金

Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
  • 批准号:
    9762469
  • 财政年份:
    2019
  • 资助金额:
    $ 106.2万
  • 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
  • 批准号:
    10179457
  • 财政年份:
    2019
  • 资助金额:
    $ 106.2万
  • 项目类别:
Third-party “off the shelf” mature or precursor CAR T cells to prevent or treat malignant relapse after allo HCT
第三方“现成的”成熟或前体 CAR T 细胞,用于预防或治疗异基因 HCT 后的恶性复发
  • 批准号:
    10417210
  • 财政年份:
    2019
  • 资助金额:
    $ 106.2万
  • 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
  • 批准号:
    10374029
  • 财政年份:
    2018
  • 资助金额:
    $ 106.2万
  • 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
  • 批准号:
    10369479
  • 财政年份:
    2018
  • 资助金额:
    $ 106.2万
  • 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
  • 批准号:
    9899952
  • 财政年份:
    2018
  • 资助金额:
    $ 106.2万
  • 项目类别:
The role of intestinal microbiota in graft-versus-host disease
肠道微生物群在移植物抗宿主病中的作用
  • 批准号:
    10524114
  • 财政年份:
    2018
  • 资助金额:
    $ 106.2万
  • 项目类别:
Endothelial cells regulate immune reconstitution after hematopoietic stem cell transplantation
内皮细胞调节造血干细胞移植后的免疫重建
  • 批准号:
    10357767
  • 财政年份:
    2018
  • 资助金额:
    $ 106.2万
  • 项目类别:
Project 2: Thymic and peripheral Aspects of T cell Aging and Rejuvenation
项目 2:T 细胞衰老和再生的胸腺和外周方面
  • 批准号:
    10226922
  • 财政年份:
    2017
  • 资助金额:
    $ 106.2万
  • 项目类别:
IL-22 in Thymic Regeneration
IL-22 在胸腺再生中的作用
  • 批准号:
    8477127
  • 财政年份:
    2012
  • 资助金额:
    $ 106.2万
  • 项目类别:

相似海外基金

HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
  • 批准号:
    10039902
  • 财政年份:
    2022
  • 资助金额:
    $ 106.2万
  • 项目类别:
    EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
  • 批准号:
    21K15925
  • 财政年份:
    2021
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
  • 批准号:
    21K08410
  • 财政年份:
    2021
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
  • 批准号:
    20K21672
  • 财政年份:
    2020
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
  • 批准号:
    18K16395
  • 财政年份:
    2018
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
  • 批准号:
    17K10951
  • 财政年份:
    2017
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
  • 批准号:
    370541
  • 财政年份:
    2017
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
  • 批准号:
    16K10863
  • 财政年份:
    2016
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
  • 批准号:
    276706135
  • 财政年份:
    2015
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
  • 批准号:
    15H04915
  • 财政年份:
    2015
  • 资助金额:
    $ 106.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了